GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPY) » Definitions » Current Ratio
中文

Hikma Pharmaceuticals (Hikma Pharmaceuticals) Current Ratio : 1.57 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

Hikma Pharmaceuticals Current Ratio Definition

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hikma Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 1.57.

Hikma Pharmaceuticals has a current ratio of 1.57. It generally indicates good short-term financial strength.

The historical rank and industry rank for Hikma Pharmaceuticals's Current Ratio or its related term are showing as below:

HKMPY' s Current Ratio Range Over the Past 10 Years
Min: 1.2   Med: 1.87   Max: 2.3
Current: 1.57

During the past 13 years, Hikma Pharmaceuticals's highest Current Ratio was 2.30. The lowest was 1.20. And the median was 1.87.

HKMPY's Current Ratio is ranked worse than
58.92% of 1076 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs HKMPY: 1.57

Hikma Pharmaceuticals Current Ratio Historical Data

The historical data trend for Hikma Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.26 1.87 2.06 1.86 1.57

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 2.12 1.86 1.79 1.57

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals Current Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Current Ratio falls into.



Hikma Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Hikma Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=2100/1339
=1.57

Hikma Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=2100/1339
=1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals  (OTCPK:HKMPY) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Hikma Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (Hikma Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (Hikma Pharmaceuticals) Headlines

From GuruFocus

Hikma Launches New 503B Sterile Compounding Business

By PRNewswire PRNewswire 01-10-2022

Hikma launches generic Advair Diskus� following FDA approval

By PRNewswire PRNewswire 12-18-2020